Proficiency testing of Hb A1c: A 4-year experience in Taiwan and the Asian Pacific region

Clinical Chemistry

Volumn 55, Issue 10, 2009, Pages 1876-1880

  Shiesh, Shu Chu ^a   Wiedmeyer, Hsiao Mei ^b   Kao, Jau Tsuen ^c   Vasikaran, Samuel D ^d   Lopez, Joseph B ^e  

^a NATIONAL CHENG KUNG UNIVERSITY   (Taiwan)

^b UNIVERSITY OF MISSOURI   (United States)

^c NATIONAL TAIWAN UNIVERSITY   (Taiwan)

^d ROYAL PERTH HOSPITAL   (Australia)

^e MAHSA University Bandar Saujana Putra   (Malaysia)

Author keywords

[No Author keywords available]

Indexed keywords

HEMOGLOBIN A1C;

ACCURACY; ANALYTIC METHOD; ARTICLE; ASIA; BLOOD SAMPLING; DIABETES MELLITUS; GLYCEMIC CONTROL; HEMOGLOBIN BLOOD LEVEL; HEMOGLOBIN DETERMINATION; HUMAN; LABORATORY TEST; MAJOR CLINICAL STUDY; NORMAL HUMAN; PROFICIENCY TESTING; QUALITY CONTROL; QUANTITATIVE ANALYSIS; TAIWAN;

ASIA, WESTERN; AUSTRALASIA; CLINICAL CHEMISTRY TESTS; FAR EAST; HEMOGLOBIN A, GLYCOSYLATED; HUMANS; MALAYSIA; QUALITY CONTROL;

EID: 70349678705     PISSN: 00099147     EISSN: 15308561     Source Type: Journal    
DOI: 10.1373/clinchem.2009.129726     Document Type: Article

References (21)

1. The Diabetes Control and Complications Trail Research Group. The effect of intensive treatment of diabetes on the development and progression of long-term complications in insulin-dependent diabetes mellitus. N Engl J Med 1993;329:977-986
2. UK Prospective Diabetes Study (UKPDS) Group. Intensive blood-glucose control with sulfonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes. Lancet 1998;352:837-853
3. Stratton IM, Adler AI, Neil HAW, Mettews DR, Manley SE, Cull CA, et al. The UK Perspective Diabetes Study Group. Association of glycemia with macrovascular and microvascualr complications of type 2 diabetes (UKPDS 35): prospective observational study. Br Med J 2000;321:405-412
4. The Diabetes Control and Complications Trail Research Group. Sustained effect of intensive treatment of type 1 diabetes mellitus on development and progression of diabetic nephropathy: the Epidemiology of Diabetes Interventions and Complications (EDIC) study. JAMA 2003;290:2159-2167
5. Martin CL, Alberts J, Herman WH, Cleary P, Waberski B, Greene DA, et al. Neuropathy among the Diabetes Control and Complications Trial cohort 8 years after trial completion. Diabetes Care 2006;29:340-344 (Pubitemid 44106515)
6. Sacks DB, Bruns DE, Goldstein DE, Maclaren NK, McDonald JM, Parrott M. Guidelines and recommendations for laboratory analysis in the diagnosis and management of diabetes mellitus. Clin Chem 2002;48:436-472 (Pubitemid 34174577)
7. American Diabetes Association. Standards of medical care in diabetes 2008. Diabetes Care 2008;31(Suppl):S12-54.
8. Knishnamurti U, Steffes MW. Glycohemoglobin: a primary predictor of the development or reversal of complications of diabetes mellitus. Clin Chem 2001;47:1157-1165
9. American Diabetes Association. Tests of glycemia in diabetes. Diabetes Care 2003;26(Suppl):S106-8.
10. Kilpatrick ES. Haemoglobin A1c in the diagnosis and monitoring of diabetes mellitus. J Clin Pathol 2008;61:877-883
11. Saudek CD, Herman WH, Sacks DB, Bergenstal RM, Edeiman D, Davidson MB. A new look at screening and diagnosing diabetes mellitus. J Clin Endocrinol Metab 2008;93:2447-2453 (Pubitemid 352008502)
12. Nathan DM, Balkau B, Bonora E, Borch-Johnsen K, Buse JB, Colagiuri S, et al. International expert committee report on the role of the A1c assay in the diagnosis of diabetes. Diabetes Care 2009;32:1-8.
13. Miller WG. Specimen materials, target values and commutability for external quality assessment (proficiency testing) schemes. Clin Chim Acta 2003;327:25-37.
14. Westgard JO. A war of words in laboratory medicine, part IV: a sentinel example. http://www.westgard.com/ (Accessed November 2008).
15. Haesselbarth W. Accounting for bias in measurement uncertainty estimation. Accred Qual Assur 2004;9:509-514 (Pubitemid 39091462)
16. College of American Pathologists (CAP) GHB survey summary, 2008. http://www.ngsp.org/prog/CAP/CAP08a.pdf (Accessed July 2009).
17. Marshall SM, Barth JH. Standardization of HbA1c measurement: a consensus statement. Diabet Med 2000;17:5-6. (Pubitemid 30094173)
18. Goodall I, Colman PG, Schneider HG, McLean M, Barker G. Desirable performance standards for HbA1c analysis: precision, accuracy and standardization. Clin Chem Lab Med 2007;45:1083-1097
19. Sacks DB, Arnold M, Bakris GL, Bruns DE, Horvath AR, Kirkman MS, et al. The National Academy of Clinical Biochemistry laboratory medicine practice guidelines: guidelines and recommendations for laboratory analysis in the diagnosis and management of diabetes mellitus: update. Draft guidelines, Version 1107. http://www.aacc.org/members/nacb/LMPG/OnlineGuide/DraftGuidelines/ diabetes-update/Pages/default.aspx (Accessed November 2008).
20. Steffes M, Cleary P, Goldstein D, Little R, Wiedmeyer HM, Rohlfing C, et al. Hemoglobin A1c measurements over nearly two decades: sustaining comparable values throughout the Diabetes Control and Complications Trial and the Epidemiology of Diabetes Interventions and Complications Study. Clin Chem 2005;51:753-758 (Pubitemid 40463927)
21. Geistanger A, Arends S, Berding C, Hoshino T, Jeppsson JO, Little R, et al. Statistical methods for monitoring the relationship between the IFCC reference measurement procedure for hemoglobin A1c and the designated comparison methods in the United States, Japan, and Sweden. Clin Chem 2008;54:1379-1385